Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-30,187
Closed -$1.86M 114
2025
Q1
$1.86M Buy
30,187
+352
+1% +$23.3K 1.04% 31
2024
Q4
$2.15M Sell
29,835
-986
-3% -$77K 1.15% 26
2024
Q3
$2.51M Buy
30,821
+595
+2% +$47.6K 1.26% 22
2024
Q2
$2.24M Sell
30,226
-704
-2% -$52.8K 1.2% 26
2024
Q1
$2.41M Buy
30,930
+6,031
+24% +$449K 1.29% 24
2023
Q4
$1.78M Sell
24,899
-6,663
-21% -$464K 1.01% 35
2023
Q3
$2.19M Buy
31,562
+226
+0.7% +$17.1K 1.36% 21
2023
Q2
$2.54M Sell
31,336
-4,313
-12% -$352K 1.56% 18
2023
Q1
$2.88M Buy
35,649
+907
+3% +$73K 1.78% 14
2022
Q4
$2.6M Buy
34,742
+5,952
+21% +$424K 1.74% 17
2022
Q3
$1.86M Buy
28,790
+11,521
+67% +$798K 1.38% 19
2022
Q2
$1.2M Buy
17,269
+703
+4% +$52.2K 0.85% 43
2022
Q1
$1.27M Buy
+16,566
New +$1.19M 0.78% 45

Other funds holding HOLX

Lindenwold Advisors's HOLX Position: Q2 2025 in Review

Lindenwold Advisors sold out of Hologic (HOLX) in Q2 2025, closing a stake of 30,187 shares — an estimated $1.86M sold.

Lindenwold Advisors first reported a position in HOLX in Q1 2022 and held it in 13 quarters. The position peaked at $2.88M in Q1 2023. 693 funds tracked by Wall St. Rank hold HOLX as of Q2 2025.

  • Lindenwold Advisors reported no remaining Hologic position as of Q2 2025 after selling out during the quarter.
  • Lindenwold Advisors sold 30,187 Hologic shares in Q2 2025, an estimated $1.86M.
  • Lindenwold Advisors first reported a position in Hologic in Q1 2022 and held it in 13 quarters.
  • Lindenwold Advisors's Hologic position peaked at $2.88M in Q1 2023.
  • 693 funds tracked by Wall St. Rank held Hologic as of Q2 2025.

Based on Lindenwold Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.